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OPEN The cardiac work-loop technique: 
An in vitro model for identifying and 
profiling drug-induced changes in 
inotropy using rat papillary muscles 
1,2Sophie Fletcher 1,2, Helen Maddock 1,2*, Rob S. James 1, RobWallis2 & MayelGharanei
The cardiac work-loop technique closely mimics the intrinsic in vivo movement and characteristics 
of cardiac muscle function. In this study, six known inotropes were profiled using the work-loop 
technique to evaluate the potential of this method to predict inotropy. Papillary muscles from male 
Sprague-Dawley rats were mounted onto an organ bath perfused with Krebs-Henseleit buffer. 
Following optimisation, work-loop contractions were performed that included an initial stabilisation 
period followed by vehicle control or drug administration. Six known inotropes were tested: digoxin, 
dobutamine, isoprenaline, flecainide, verapamil and atenolol. Muscle performance was evaluated 
by calculating power output during work-loop contraction. Digoxin, dobutamine and isoprenaline 
caused a significant increase in power output of muscles when compared to vehicle control. Flecainide, 
verapamil and atenolol significantly reduced power output of muscles. These changes in power output 
were reflected in alterations in work loop shapes. This is the first study in which changes in work-loop 
shape detailing for example the activation, shortening or passive re-lengthening have been linked to 
the mechanism of action of a compound. This study has demonstrated that the work-loop technique can 
provide an important novel method with which to assess detailed mechanisms of drug-induced effects 
on cardiac muscle contractility. 
Te primary function of the heart is as a mechanical pump; undergoing two main phases during each cardiac
cycle: contraction (systole) and relaxation (diastole). A change in contractility, as a result of pharmacological
interventions (inotropy) or a pathophysiological condition, would therefore impact on the hearts intrinsic abil-
ity to act as a mechanical pump. Hence, it is important to have a reliable index of contractility both in vivo and
in vitro. 
Te most reliable way to measure changes in contractility in vivo is by measuring changes in lef ventricular
pressure and volume, as frst suggested by Suga and Sagawa1. Te relationship between pressure and volume has
since become a widely accepted index of cardiac contractility2. Because of the general applicability of this concept
to hearts of all species, pressure-volume analysis has become the favoured practice for assessing contractility in
pre-clinical studies of all mammals including mice, dogs and non-human primates. Telemetry studies involving
conscious animals are ofen considered to be the gold standard for pre-clinical contractility assessment; ofen by 
measuring changes in pressure or volume or other measures such as LVDP/dt max3. However, the use of teleme-
try is expensive, has a relatively slow throughput, and requires the use of live animals. Hence, such measurements
are ofen carried out late in the development of new pharmacological compounds. 
Although the pressure-volume relationship is the most direct and reliable way to measure contractility in vivo, 
in a clinical setting the pressure-volume relationship is rarely measured directly to assess changes in contraction 
and heart function. Te use of conductance catheters to measure this relationship is highly reliable, however, it
is invasive, complex, expensive and technically demanding2. One technique routinely used to identify changes
in cardiac performance and contractility in a clinical setting is the method of echocardiography; it is currently
recommended by National Institute for Health and Care Excellence in the diagnosis andmonitoring of acute and 
chronic heart failure4,5. Echocardiograms are commonly used to assess the structure and function of the heart.
Function is quantifed using estimations of cardiac output, ejection fraction and diastolic function. Te biggest
1Centre for Sport, Exercise and Life Sciences, Coventry University, Coventry, United Kingdom. 2InoCardia Ltd,
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advantages of echocardiography are that it is non-invasive and relatively inexpensive meaning it can be used
routinely. However, haemodynamic parameters such as cardiac output and ejection fraction are not measured
directly but estimated based on other measurements6,7, meaning there is a higher degree of error compared to
more direct measurements. 
It is important to have a reliable in vitro measure of cardiac contractility which can be used in a translative
manner in order to predict changes in vivo and to help us better understand complex pathophysiological condi-
tions. Tere are many in vitro techniques which can be used to assess contractility, ranging from whole heart to
those using single cardiomyocytes. A well-established in vitro technique commonly used to assess changes in con-
tractility is the Langendorf perfused heart model8. Te Langendorf technique utilises the whole heart (routinely
small mammals such as rats or mice) which is perfused in a retrograde manner under constant pressure. One of
the main benefts of this technique is that there are no difusion constraints as the vasculature of the heart is uti-
lised in the perfusion of compounds it is also possible to acquire electrocardiogram traces during experiments8. 
One of the main disadvantages is that there is a lack of aferload which does not refect biomechanics in vivo. 
Muscles isolated from the myocardium can also be utilised in vitro and are predominantly used in isometric
contraction studies, during which the muscles are held at a constant length and stimulated to produce a twitch
response9,10. However, in vivo cardiac muscle is rarely at constant length during contraction and relaxation, hence,
isometric contraction studies do not fully replicate the dynamic cardiac muscle movement observed in vivo. 
Isometric contraction studies also overestimate the power output of a muscle as they do not account for the fact
that muscles cannot be continuously maximally activated; time is required for relaxation, re-lengthening and
activation11–14. 
Another class of techniques currently used experimentally to assess contractility are cellular assays such as
impedance- or sarcomere shortening- assays15–18. Tese techniques have the potential to be higher throughput
than those mentioned previously. However, one main drawback of these methods is that generally the cardiomy-
ocytes are unloaded which is not representative of in vivo conditions. Also, impedance is not a direct measure of 
contraction but merely a surrogate. 
In isolated muscles or cells, it is not possible to measure changes in pressure and volume because the atria
and ventricles are no longer intact. In the cardiac work-loop technique changes in force and length are measured 
instead. Te technique incorporates a sinusoidal length change along with electrical stimulation that closely mim-
ics the cardiac cycle in vivo and has the potential to be used pre-clinically to identify changes in contractility. It
has been suggested that strain patterns that occur in vivo are almost sinusoidal in shape19,20, whilst the exact strain
patterns are more complex in nature, a sinusoidal length change ofers a good approximation of in vivo muscle 
mechanics21. 
Te work-loop technique has previously been utilised in studies of both skeletal11,22,23 and cardiac mus-
cle12,24–29. Layland et al.28 have previously investigated the efect of 5µM isoprenaline and 100µM of phenyle-
phrine on the power output of isolated rat ventricular trabeculae muscles. Tis study successfully demonstrated
that both isoprenaline and phenylephrine increased the power output of the trabeculae muscles using the cardiac
work-loop technique and hence were positive inotropes. However, the study was not performed at a physiologi-
cally relevant temperature (24 °C) and relatively high concentrations of both compounds were used. 
Prior to the current study, extensive work has been carried out in our laboratory in order optimise the cardiac 
work-loop technique using rat papillary muscles under physiologically relevant conditions (temperature, length
change and cycle frequency) (data not published). 
In the current study, isolated rat papillary muscles were used to assess the ability of the cardiac work-loop
technique to identify drug-induced changes in contractility by testing six known inotropes. Te power output
of the muscles was measured and compared statistically to a suitable vehicle control. Te shape of the work-loop 
during drug treatment was compared to that during stabilisation and any changes in the work-loop shape were
linked to the mechanism of action of the compound. Te aim of the study was to demonstrate that the car-
diac work-loop using rat papillary muscles has the potential to be used as an in vitro technique to identify drug
induced changes in contractility. 
Materials and Methods 
Chemicals. Isoprenaline hydrochloride, atenolol and verapamil hydrochloride were purchased from Abcam 
(Cambridge, UK). Dobutamine hydrochloride, digoxin and flecainide acetate were purchased from Tocris
Bioscience (Oxford, UK). Stock solutions (1–10mM) of all compounds were made and were stored at −20 °C.
Digoxin and dobutamine were dissolved in dimethyl sulfoxide (DMSO) to make the stock solution. Te fnal
concentration of DMSO during experimentation was less than 0.01%. Verapamil, atenolol, fecainide and isopren-
aline were all dissolved in ultra-pure water to make the stock solution. All other reagents were purchased from
either Sigma Aldrich (Dorset, UK) or Fisher Scientifc (Loughborough, UK) unless stated otherwise. 
Animals. Male Sprague-Dawley rats were used in all experiments; they were obtained from Charles River
(Margate, UK) and housed at the University of Warwick. Experiments were conducted in accordance with the
Guidelines on the Operation of Animals (Scientifc Procedures Act 1986) and were approved by the Coventry
University ethics committee. 
Papillary muscle dissection. Muscle preparation was similar to that previously described12. Rats were
sacrifced via cervical dislocation; the hearts were then carefully and rapidly excised and placed into ice-cold,
oxygenated (100% O2) Krebs Henseleit (KH) bufer. Te KH bufer comprised of: NaCl (144mM), Na Pyruvate
(10mM), HEPES [4-(2-hydroxyethyl)−1-piperazineethanesulfonic acid] (10mM), KCl (6mM), CaCl2·2H2O 
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 Figure 1. Depiction of protocols used. Work-loops were carried out every 5 minutes during the protocols. 
(2mM), MgCl2·6H2O (1mM), NaH2PO4 (1mM) and MgSO4·7H2O (1mM). Te bufer was oxygenated and
heated to 37 °C for 30minutes. Te pH was adjusted to 7.40 using 5M NaOH prior to its use. 
Dissections were carried out under a dissecting stereomicroscope using a petri-dish containing Sylgard
184 Silicone Elastomer Polymer (Farnell, UK). Troughout the dissections, the tissue was submerged in cold
(2 °C–4°C), oxygenated KH bufer which was regularly discarded and replaced. Te heart was carefully pinned to
the dish then a small incision was made at the apex using microfne scissors. Cuts were made carefully along the 
wall of the lef ventricle and along the intraventricular septum exposing the papillary muscles. Papillary muscles 
were then selected based on size and shape; a T-clip (a small T-shape made of tin foil) was attached to either end 
of the chosen muscle. Following dissection, the muscles were placed onto a work-loop rig consisting of: a horizon-
tal organ bath (which included platinum stimulating electrodes and a micromanipulator), high-speed length con-
troller, 100mN/50mN capacity force transducer, stimulator, thermocouple and signal interface (all from Aurora 
Scientifc, Canada). Te organ bath was perfused with recirculating KH bufer, which was gassed continuously.
Te temperature within the organ bath was maintained at 37 °C throughout the experiments. Te muscles rested 
under a passive force of ~0mN for at least 20minutes before length optimisation. 
Muscle length optimisation. Once the muscles had acclimatised to 37 °C, the muscles were slowly
stretched using a micromanipulator resulting in a small amount of passive force (around 3mN), they were then
stimulated while kept at a constant length (isometric). Te stimulation produced an isometric twitch and the
developed force was calculated by bespoke sofware by subtracting the minimum force (passive force) from the
maximum force (active force). Te sofware used had been developed in-house; it was used for length optimisa-
tion and work-loop protocols it was able to display real-time work-loop data during work-loop protocols. 
Te length was increased incrementally, and a stimulus delivered at each length, until a muscle length at
which maximum developed force was reached (Lmax). Te length of the muscle was measured using a microscope
ftted with an eyepiece graticule and was then adjusted to 90% of Lmax (in accordance with preliminary optimisa-
tion experiments, data not shown here). 
Work-loop protocol. Figure 1 shows the two protocols used, during both protocols, work-loop contrac-
tions were carried out every 5minutes for 80minutes. As detailed, the frst 20minutes was used as a stabilisation 
period to determine baseline muscle performance. Preparations that were unstable during the stabilisation period
(greater than 20% variation in power output from the mean value during stabilisation) were excluded from the
data set. Following the stabilisation period, muscles in the vehicle control groups were perfused with either KH
bufer or 0.01% DMSO solution (dissolved in KH bufer). A wash-out was not included in this protocol in order
to increase the throughput of the technique. 
During all experiments, work-loop contractions were carried out using the following parameters: initial
length of 90% Lmax, strain amplitude= ±4%, cycle frequency=6Hz, pulse width of stimulation=1.0ms and a
current of 120mA was used for all stimulations (parameters were established during preliminary optimisation
experiments, data not shown). 
At the end of the experiments, the wet muscle mass was measured to the nearest 0.00001 g using an elec-
tronic balance (Sartorius BP211D, Germany). Muscle mass, fbre length and the assumed muscle density of
1060kgm−3 12,30 were used to calculate fbre cross-sectional area and the isometric muscle stress. 
Analysis. Work-loop traces were produced by plotting the force against the length (or strain) of the muscle.
Figure 2 depicts a typical cardiac work-loop and its three main phases. It also depicts how net work can be cal-
culated based on the net area of the loop. In this study net power output was calculated which is proportional to
the net work. Instantaneous power was calculated for each data point (1667 points per loop) by multiplying the
instantaneous force by the instantaneous velocity12. Te instantaneous power output values were then averaged to
give average net power output value. Te average net power output value was then adjusted to account for muscle
mass. For each of the time courses, the power output during the vehicle- or drug- treatment was expressed as a
percentage of the average power output during stabilisation. 
All six drug treatments were compared to a time-matched vehicle control treatment. Te data were expressed 
as mean± SEM. Power output values were assessed for statistical diferences, p<0.05 was considered statisti-
cally signifcant. A repeated measure two-way analysis of variance (ANOVA) was performed, if the ANOVA was 
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Figure 2. Adapted from Gharanei et al. 2014 showing: (a) typical force, (b) length and (c–f) work-loop traces. 
Te cardiac work-loop consists of three main phases which have been labelled in each diagram. (a) typical 
force trace of a cardiac work-loop. (b) typical sinusoidal length trace of a cardiac work-loop. (c) typical work-
loop trace showing 3 main phases: (1) Activation of the muscle. (2) Shortening of the muscle (3) Passive re-
lengthening of the muscle. (d) Phase 1 is highlighted- during this phase the muscle is simultaneously stimulated 
electrically and lengthened. Te shaded area depicts the work required to lengthen the muscle from initial 
length to maximum length. (e) Phase 2 is highlighted- once the peak force has been reached the length of the 
muscle is shortened to below that of the original length. Te force gradually decreases during this period. Te 
area highlighted during this phase is the total work done during shortening. (f) Phase 3 is highlighted- during 
this phase the muscle is re-lengthened back to its starting length. Te area highlighted is the work required to 
re-lengthen the muscle to initial length. Te net work, which corresponds to the area within the loop can be 
calculated as: area 2 – (area 1+area 3). 
KH Vehicle 
Control (n=7) 
0.01% DMSO Vehicle 
Control (n=7) 
Digoxin 
(n=6) 
Dobutamine 
(n=9) 
Isoprenaline 
(n=7) 
Verapamil
(n=7) 
Flecainide 
(n=7) 
Atenolol
(n=8) 
Lmax (mm) 2.10±0.71 2.71±0.72 1.85±0.57 2.19±0.41 1.70±0.62 2.18±0.52 2.20±0.87 2.45±0.45 
Active Force (mN) 17.4±4.5 23.2±6.5 17.3 ±3.8 23.1±7.4 19.9±4.3 21.5±8.3 24.4±10.8 20.7±7.5 
Passive Force (mN) 5.4±1.4 6.2±2.1 6.1±1.5 7.5±1.3 7.1±1.4 5.8±1.6 8.2±1.3 5.8±2.1 
Developed Force (mN) 11.9±3.5 17.0±5.3 11.2±3.1 15.6±6.2 12.8±3.1 15.7±7.6 15.5±10.1 14.8±6.4 
Fibre CSA (m2) 3.2× 10
−7 ±
1.2× 10−7 
2.7× 10−7 ±
1.0× 10−7 
4.3× 10−7 ±
2.6× 10 −7 
2.7× 10−7 ±
1.1× 10−7 
2.5× 10−7 ±
1.4× 10−7 
4.1× 10−7 ±
1.2× 10−7 
2.7× 10−7 ±
1.1× 10−7 
3.0× 10−7 ±
1.4× 10−7 
Isometric Stress (kNm−2) 41±16 65±10 37±23 60±15 56±21 41±25 49±19 48±16 
Muscle Mass (µg) 677±282 772±304 778±397 636±305 554±452 866±392 684±481 873±431 
Average net power (end of 
stabilisation) (Wkg−1) (at 90% Lmax) 
9.9±4.7 18.2±3.5 10.1±6.7 15.1±4.0 14.8±8.1 9.7±4.4 16.4±7.8 14.2±4.8 
Table 1. Characteristics of papillary muscle preparations. Lmax, length at which maximum force was produced; 
CSA, cross-sectional area. Unless specifed all values are for when the muscle is at length Lmax Values are 
mean±SD (n=6–9). 
signifcant (p<0.05) independent sample t-tests were performed for each time point. Te two vehicle control
groups (KH bufer and 0.01% DMSO) were also compared to each other using a two-way repeated measure
ANOVA, there was no signifcant diference in the power output (p=0.104). 
During the initial nine dobutamine experiments four experiments had to be excluded from the analysis and
repeated. In these cases, dobutamine treatment caused the muscles to contract spontaneously causing the muscle 
to fatigue, resulting in work-loops which did not represent the true power output of the muscle. 
Results 
Muscle characteristics. Te characteristics of the muscle preparations following length optimisation and
before any drug or control treatment are shown in Table 1. All experimental groups were compared using a one- 
way ANOVA (analysis of variance) with post-hoc Bonferroni test. Tere were no signifcant diferences (p>0.05)
between the experimental groups for the following characteristics: Lmax, active force, passive force, developed
force, fbre CSA and stress (all at Lmax), muscle mass and net power output at the end of stabilisation. 
Drug induced changes on muscle performance. For all six drug treatments, a time-course and a pair
of representative work-loops have been presented in the fgures below (Figs. 3, 4, 5, 6, 7, 8). Te time-course
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Figure 3. (a) Te efect of digoxin administration on the power output of the muscle (n=6) compared to 
the vehicle control treatment (n=7). All muscles underwent a 20-minute stabilisation period (shown in 
grey); followed by 60 minutes of either control- or drug- treatment. Te power values for the control- and 
drug- treatment are expressed as a percentage of the average value during stabilisation. Values are presented as 
mean±SEM. (n=6–7). Two-way repeated measures ANOVA followed by independent samples t-test for each 
time point DMSO vehicle control vs Digoxin: *p<0.05, **p<0.01 and ***p<0.001. (b) Te efect of digoxin on 
representative work-loop shapes. Te black dashed loop is from the end of the stabilisation period (20 minutes), 
the red loop is from the point of maximal drug response (55 minutes overall). 
depicts the mean (±SEM) power output of the muscle preparations over 80minutes. Te efect of positive and
negative inotropes on the power output of the muscle over time are demonstrated and how they compare to the
time-matched vehicle treatment. For the representative work-loops a loop from the end of stabilisation (20min-
utes) has been compared to a work-loop from the time point of maximal drug response (based on power output
values). 
Positive inotropes. As shown in Fig. 3a, digoxin (1µM) caused a signifcant and sustained increase in the
power output of the muscle. Afer 10minutes of treatment, digoxin caused a signifcant (p=0.033) increase in
power output when compared to the time-matched vehicle control; a signifcant diference was maintained for
the remainder of the experiment. Te greatest increase in contractility was observed 30minutes into the drug
treatment with an increase in power output of 27% (±9%) compared to the vehicle control treatment (p=0.001).
Digoxin elicited its efect primarily during the second phase of the work-loop where it caused an increase in
the force throughout muscle shortening, there was also an increase in the peak force when compared to the
work-loop from stabilisation (Fig. 3b). 
Dobutamine (1µM) also caused a signifcant increase in the power output of the muscle (Fig. 4a). Afer 5min-
utes of drug treatment, dobutamine caused a signifcant increase in the power output of the muscle (p=0.005)
when compared to time-matched controls. Te maximal response was recorded 10minutes into the drug treat-
ment with an increase in power output of 20% (±6%) when compared to the vehicle control treatment. A signif-
icant increase in power output was sustained for the remainder of the experiment. Dobutamine elicited its efects 
during the active phase of the loop and the passive re-lengthening of the muscle (Fig. 4b). An increase in the peak
force was observed, however, this increase in force was not sustained throughout the whole of the second phase.
During the third phase, the force during re-lengthening was lower compared to stabilisation which reduced the
negative work during re-lengthening to initial length and hence net power output. 
Isoprenaline (30nM) caused a signifcant increase in power output of 14% (±9%) afer 10minutes of drug
treatment when compared to the control (p=0.03) (Fig. 5a). During the remainder of the experiment, the drug
induced increase in muscle performance declined and reached power values comparable to the vehicle values.
Isoprenaline also elicited its efects during the second and third phase of the work-loop in a similar manner
to dobutamine causing an increase in peak work-loop force and a lower force during re-lengthening to initial
length Fig. 5b. 
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Figure 4. (a) Te efect of dobutamine administration on the power output of the muscle (n=9) compared to 
the control treatment (n=7). All muscles underwent a 20-minute stabilisation period (shown in grey); followed 
by 60 minutes of either control- or drug- treatment. Te power values for the control- and drug- treatment 
are expressed as a percentage of the average value during stabilisation. Values are presented as mean±SEM. 
(n=7–9). Two-way repeated measures ANOVA followed by independent samples t-test for each time point 
DMSO vehicle control vs Dobutamine: *p<0.05, **p<0.01 and ***p<0.001. (b) Te efect of dobutamine on 
representative work-loop shapes. Te black dashed loop is from the end of the stabilisation period (20 minutes), 
the red loop is from the point of maximal drug response (30 minutes overall). 
Negative inotropes. Verapamil (1µM) caused a signifcant (p=0.05) decrease in the power output of the
muscle afer 40minutes of drug treatment (60minutes overall) when compared to the time-matched control
(Fig. 6a). Te largest diference in power output was observed 45minutes into the drug treatment, the power out-
put was 17% (±9%) lower compared to the time-matched vehicle control treatment. A signifcant reduction in
power output was sustained for the remainder of the time course. Verapamil elicited its efects during the second 
and third phase of the work-loop causing a reduction in the force produced by the muscle during both phases
including a reduction in the peak force when compared to stabilisation (Fig. 6b). 
Flecainide 3µM caused a signifcant (p=0.009) decrease of 16% (±6%) in the power output afer 40minutes 
of drug treatment when compared to the control (Fig. 7a). Tis decrease in power output remained signifcant
until the end of the drug treatment (p<0.05). Figure 7b shows that fecainide caused a reduction in the force
produced by the muscle throughout all three phases of the work-loop including a reduction in the peak force at
the beginning of phase 2. 
Atenolol 20µM caused a signifcant (p=0.046) reduction of 13% (±7%) in the power output of the muscle
afer 45minutes of drug treatment (Fig. 8a). Figure 8b shows that atenolol caused a reduction in the force pro-
duced by the muscle during the second and third phase of the work-loop. 
Discussion 
Te heart is a dynamic organ and cardiac contraction is made possible by a complex interplay between the elec-
trical and structural changes that directly result in the specifc function of the heart31. Te process is complex and
specifc meaning a small change in the structural, electrical or other changes can result in signifcant changes in
the performance of the heart and its function. It is therefore imperative to regard the structural biomechanics of
the heart when designing in vitro contractility assays. 
In this study, six known inotropes have been used to assess the suitability of the cardiac work-loop technique 
for identifcation of inotropes. Each of the compounds tested caused a signifcant change in the power output of
the muscle when compared to the appropriate vehicle control. Digoxin, dobutamine and isoprenaline caused sig-
nifcant increases in the power output (Fig. 9) of the muscle and were therefore successfully classifed as positive 
inotropes. Verapamil, fecainide and atenolol caused a signifcant decrease in the power output (Fig. 9) and were 
successfully classifed as negative inotropes. Te compounds used in this study were chosen because their activity
in vivo and in vitro has been well documented within the literature. Table 2 details how the concentrations used in
this study compare to other in vitro studies and human in vivo studies. 
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Figure 5. (a) Te efect of isoprenaline administration on the power output of the muscle (n=7) compared to 
the vehicle control treatment. All muscles underwent a 20-minute stabilisation period (shown in grey); followed 
by 60 minutes of either vehicle- or drug- treatment. Te power values for the control- and drug- treatment are 
expressed as a percentage of the average value during stabilisation. Values are presented as mean±SEM. (n=7). 
Two-way repeated measures ANOVA followed by independent samples t-test for each time point KH vehicle 
control vs Isoprenaline: *p<0.05. (b) Te efect of isoprenaline on representative work-loop shapes. Te black 
dashed loop is from the end of the stabilisation period (20 minutes), the red loop is from the point of maximal 
drug response (30 minutes overall). 
Positive inotropes. Work-loop data presented here shows that digoxin (1µM) signifcantly increased cardiac
muscle performance and caused elevated forces during muscle shortening as observed from the work-loop shape
(Fig. 3). Digoxin is a cardiac glycoside and inhibits sodium-potassium ATPase (Na+/K+ ATPase)32. Inhibition
causes an increase in the levels of intracellular sodium, reducing the concentration gradient of sodium which
in turn decreases the activity of the sodium-calcium exchanger. As a result, less calcium is transported out of
the cell leading to an increase in the concentration of intracellular calcium; triggering release of further calcium
from the sarcoplasmic reticulum. Te dose-dependent efect of intracellular calcium on contractility is well doc-
umented33,34 and is in part due to higher level of calcium binding to troponin C as it is one of the main regulators 
of contraction in cardiac muscle35. Digoxin does not afect the activation or relaxation of cardiac tissue, refected 
in no efect being seen during the activation and passive re-lengthening phases of the cardiac work-loop (Fig. 3b).
As detailed in Table 2, the concentration of digoxin used here was comparable to the concentration used in other 
in vitro contractility experiments36–39. Rosic et al.38 reported roughly a 25% increase in lef-ventricular diastolic
pressure following infusion of 5µM Digoxin in Langendorf perfused guinea pig hearts. Guo et al.39 reported that
1µM Digoxin caused a 31% increase in Ca2+ -wave amplitude in human induced pluripotent stem cell cardiomy-
ocytes (hiPSC-CM)39. 
Both dobutamine and isoprenaline are adrenoreceptor agonists; dobutamine is predominantly a β1 
and α1 receptor agonist with weak β2 activity, isoprenaline activates both β1 and β2 receptors. Activation of
β1-adrenoreceptors activates the GS subunit of the adrenoceptor which initially directly activates the L-type cal-
cium channel. Secondly, it activates adenylyl cyclase to form cAMP using ATP. An increase in the level of cAMP 
activates cAMP dependent protein kinase (protein kinase A) which phosphorylates numerous targets including: 
L-type calcium channels, phospholamban and troponin I40. Phosphorylation of L-type calcium channels results
in a greater availability of intracellular calcium during systole which consequently increases contractility during
the subsequent diastole40. Tis efect was observed in this study as an increase in force during shortening of
the muscle. Phosphorylation of phospholamban causes more rapid removal of calcium from the cytosol into
the sarcoplasmic reticulum enhancing relaxation of the muscle. Finally, enhanced calcium dissociation from
myoflaments during diastole due to phosphorylation of troponin I which enhances relaxation of the muscle40,41. 
Increased levels of relaxation were also observed experimentally with lower forces being recorded during passive 
re-lengthening of the muscle. Layland et al.28 also observed an acceleration of twitch relaxation with 5µM of 
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Figure 6. (a) Te efect of verapamil administration on the power output of the muscle (n=7) compared to 
the control treatment. All muscles underwent a 20-minute stabilisation period (shown in grey); followed by 
60 minutes of either control- or drug- treatment. Te power values for the control- and drug- treatment are 
expressed as a percentage of the average value during stabilisation. Values are presented as mean±SEM. (n=7). 
Two-way repeated measures ANOVA followed by independent Two-way repeated measures ANOVA followed 
by independent samples t-test for each time point comparing Verapamil and KH Vehicle Control: *p<0.05. 
(b) Te efect of verapamil on representative work-loop shapes. Te black dashed loop is from the end of the 
stabilisation period (20 minutes), the red loop is from the point of maximal drug response (65 minutes overall). 
isoprenaline. Brown and Erdmann10 observed ~60% increase in the isometric force in cat papillary muscles when
perfused with ~50µM dobutamine this is a similar amplitude of response as observed in this study at 1µM. 
Although both isoprenaline and dobutamine elicit their efects through similar mechanisms and their efects 
on the shape of the work-loop are similar, the magnitude and duration of the inotropic efect was much lower
with isoprenaline. Tis may in part be due to the concentration of isoprenaline used. A dose response study was
carried out for isoprenaline 10nM–1µM (data not shown here); it was found that concentrations of 100nM and
above caused the muscle to contract spontaneously as a result of its chronotropic and proarrhythmic properties.
Hence, in this study a concentration of 30nM was used. Te addition of a chelating agent such as EDTA or EGTA
would have inhibited the oxidation of isoprenaline28 and may have resulted in a greater increase in power output. 
Negative inotropes. Verapamil causes negative inotropy by blocking both L-type and T-type voltage-gated 
calcium channels42. Tis causes a decrease in the intracellular calcium levels which reduces the probability of
the opening of the intracellular ryanodine receptors43. As a result, treatment with verapamil reduces both the
probability of contraction and the force of contraction. Verapamil reduced the power output of the muscle during
shortening and also reduced the force required to re-lengthen the muscle, it had no efect on the activation of the 
muscle (Fig. 6b) As shown in Table 2, the concentration used in this study is comparable to the concentration
tested previously by Noguchi et al.44; a cumulative dose-response (1nM–100µM) for verapamil was carried out
using guinea pig papillary muscles which underwent isometric contractions at frequency of 1Hz. At a cumula-
tive dose of 1µM the developed force was ~40% compared to the control, however, the duration of each dose is
unknown. In the current study the duration of drug treatment was restricted to 60minutes meaning verapamil
may not have elicited its maximal efect. 
Flecainide is a Nav1.5 sodium channel blocker and an inhibitor of ryanodine receptor 2 (RyR2)45. RyR2 is a
major regulator of the release of calcium from the sarcoplasmic reticulum and so inhibition results in a reduction
in contraction. In this study, fecainide has been shown to be a negative inotrope it has been shown to exhibit its
efects during the shortening and passive re-lengthening phases of the work-loop (Fig. 8b). A dose response for
fecainide was also carried out 0.3µM–10µM (data not shown here), whereby a small but signifcant negative
efect was observed at 0.3µM which is comparable to the clinical concentration in Table 2. In an isometric con-
traction study46 fecainide was tested using rabbit papillary muscles. Josephson et al. observed a decrease in devel-
oped force of around 20% at a concentration of 5µg/ml (~12µM) and a signifcant decrease (p<0.005) of around
30% at a concentration of 10µg/ml (~24µM). Te magnitude of the response is comparable to this study, however,
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Figure 7. (a) Te efect of fecainide administration on the power output of the muscle (n=7) compared to 
the control treatment. All muscles underwent a 20-minute stabilisation period (shown in grey); followed by 
60 minutes of either control- or drug- treatment. Te power values for the control- and drug- treatment are 
expressed as a percentage of the average value during stabilisation. Values are presented as mean±SEM. (n=7). 
Two-way repeated measures ANOVA followed by independent samples t-test for each time point comparing 
Flecainide and KH Vehicle Control: *p<0.05 and **p<0.01. (b) Te efect of fecainide on representative work-
loop shapes. Te black dashed loop is from the end of the stabilisation period (20 minutes), the red loop is from 
the point of maximal drug response (60 minutes overall). 
the concentrations used were signifcantly higher. Flecainide was tested in a cumulative concentration-response
study using human trabecular bundles47; 3µM fecainide caused ~15% reduction in peak isometric force com-
pared to vehicle. Tis response was not signifcant (p>0.05) however the magnitude of the response is compa-
rable to this study. 
In this study, atenolol has been shown to be a negative inotrope. Atenolol is a β1-adrenergic receptor blocker; it
blocks endogenous adrenaline and noradrenaline. It has been demonstrated that electrical stimulation of isolated
cardiac muscle elicits a contraction accompanied by noradrenaline release48,49. It has also been demonstrated
that this adrenergic response to feld stimulation can be markedly reduced by propranolol (a β1 and β2 adrener-
gic receptor blocker). Terefore, atenolol may also signifcantly reduce noradrenaline release and hence reduce
contractility50. Atenolol also acts as an inverse agonist on β1 and β2 adrenoceptors, blocking receptors which are
constitutively active9,51. It is hypothesised that the observed response was due to atenolol blocking endogenous
adrenaline and noradrenaline and also acting as an inverse agonist. Atenolol exhibited its efects during the short-
ening and passive re-lengthening phases of the work-loop. Varma et al.9 tested atenolol at various concentrations 
in the right atria, lef atria, right ventricles and isolated papillary muscles from the rat myocardium. Tey carried 
out isometric contractions at a frequency of 1Hz. Tey found that there was no diference in contractile force
when papillary muscles were treated with atenolol (10nM–100µM). A signifcant efect was measured in both
the right and lef atria at concentrations of above 100nM. Kerns et al.52 tested atenolol using the rat Langendorf 
perfused heart model. Using a concentration of 25mg/mL (~9.4µM) atenolol signifcantly (p<0.05) reduced lef 
ventricular pressure afer 60minutes. Clinically, atenolol has been observed to cause a reduction in systolic and
diastolic blood pressures of around 15% and a reduction in cardiac output of around 20%53 which is of similar
magnitude to the reduction in power that has been observed in this study. 
In the present study, the work-loop technique incorporated an electrical stimulation along with a sinu-
soidal length change which mimics the cardiac cycle in vivo more closely than other contractility techniques.
Incorporating a physiologically relevant length change is one of the main advantages of the work-loop technique 
over other in vitro techniques such as isometric contraction studies. Tis work has successfully shown that the
cardiac work-loop technique is useful in assessing the efects of inotropic agents on cardiac muscle contractility
since it is sensitive to changes in force, velocity, activation rate and frequency. Further assessment of the efects
of: phosphodiesterase type 3 inhibitors (e.g. pimobendan or milrinone), calcium sensitizers (e.g. levosimendan), 
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Figure 8. (a) Te efect of atenolol administration on the power output of the muscle (n=7) compared to 
the control treatment. All muscles underwent a 20-minute stabilisation period (shown in grey); followed 
by 60 minutes of either control- or drug- treatment. Te power values for the control- and drug- treatment 
are expressed as a percentage of the average value during stabilisation. Values are presented as mean±SEM. 
(n=7–8). Two-way repeated measures ANOVA followed by independent samples t-test for each time point KH 
vehicle control vs Atenolol: *p<0.05. (b) Te efect of atenolol on representative work-loop shapes. Te black 
dashed loop is from the end of the stabilisation period (20 minutes), the red loop is from the point of maximal 
drug response (60 minutes overall). 
Figure 9. Maximal drug response for each compound when compared to appropriate vehicle control, results 
presented as mean±SEM. *p=0.046 atenolol vs KH vehicle control (60 minutes overall), ##p=0.009 fecainide 
vs KH vehicle control (60 minutes), £p=0.041 verapamil vs KH control (75 minutes), @p=0.03 isoprenaline 
vs KH control (30 minutes), $$$p=0.0004 dobutamine vs 0.01% DMSO control (30 minutes), +++p=0.001 
digoxin vs 0.01% DMSO control (55 minutes). 
Na2+ channel blockers (e.g. disopyramide) and those with more complex mechanisms of action (e.g. amitripty-
line, quinidine) would support additional validation of the work-loop assay in the future. 
In conclusion we have demonstrated that the work-loop model provides a more physiologically realistic
technique for studying isolated cardiac muscle. Te work-loop model enables the mechanical work of the mus-
cle to be assessed. Tis is the frst study in which known inotropes of various classes have been tested in the
cardiac work-loop at a physiologically relevant temperature in order to assess its suitability as a contractility
assay. By correctly identifying the inotropes this technique has been shown to have the potential to be used
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Compound 
Concentration used 
in this study (µM) 
In vitro studies Human in vivo studies 
Solution
concentration (µM) Reference 
Plasma concentration 
(ng/ml) 
Estimated free 
concentration (µM) Reference 
Digoxin 1 
30 36 
1.32 0.002 54
0.3, 1 37 
5 38 
0.03–10 39 
Dobutamine 1 0.1–10 10 200 0.5 55 
Isoprenaline 0.03 
5 27 
0.5 0.002 56 
5 28 
Verapamil 1 0.001–10 44 40 0.01 57 
Flecainide 3 
12,24 46 
296 0.4 59 
0.01–100 58 
Atenolol 20 
0.01–30 9 
550 0.2 60 
~9.4 52 
Table 2. Comparison between the concentration of compounds used in this study and concentrations 
used in other in vitro studies and the estimated free concentration which is based on the measured plasma 
concentration. 
as a preclinical assay for contractility. Tis type of work-loop model has the potential to enable researchers to
understand mechanical defects underlying cardiac diseases and subsequently study drug efects in various dis-
ease conditions. Tis is the frst study in which changes in work-loop shape detailing for example the activation,
shortening or passive re-lengthening have been linked to the mechanism of action of the compound and is a
useful method with which to assess detailed mechanisms of drug-induced efects on cardiac muscle contractility. 
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